Certara upgraded to Overweight from Equal Weight at Barclays

Barclays analyst Luke Sergott upgraded Certara (CERT) to Overweight from Equal Weight with a price target of $14, up from $11. The firm believes the company is more favorably positioned with potential macro and policy headwinds versus the majority of its peers sector. Shares at current levels offer an attractive entry point, the analyst tells investors in a research note. While it is still early days, Certara’s simulation modeling functions more in the earlier stages of drug discovery, and the business is well positioned to capture Tailwinds from the transition away from animal models, contends Barclays.